By analyzing the expression levels of LGMN in the serum of GC patients sensitive and resistant to PD-1 mAbs, we found that the expression level of LGMN in the serum of anti-PD-1-resistant GC patients was significantly higher than that in sensitive patients. Here, LGMN is linked to gastric cancer.